The agency pushed its decision on weekly subcutaneous LEQEMBI IQLIK for early Alzheimer's initial treatment to Aug. 24 after ...

Biogen Inc. BIIB shares are trading higher on Friday as the company is continuing its FDA review process for Leqembi Iqlik ...

Specifically, the FDA is delaying its verdict on once-weekly Leqembi Iqlik (lecanemab) as a starting dose for patients ...

Biotech company Biogen (NASDAQ:BIIB) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 1.9% ...

Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Wednesday before the bell. Here’s what you need to know.

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period ...

Prominent biotech Biogen (NASDAQ: BIIB) loomed large on the stock market on Wednesday. It published its latest set of ...

Biogen’s growth was expected to stay flat through the 2030s. A key acquisition and busy late-stage pipeline have relieved the ...

Biogen (BIIB) stock is in focus as the company beats forecasts with its Q1 2026 financials and trims its full-year earnings ...

On Apellis, "we have the proposed Apellis acquisition" and "we do expect the acquisition to be accretive in 2027" (CEO Viehbacher). "Total revenue was $2.5 billion" and "non-GAAP diluted EPS of $3.57" ...

Regulatory delay: The FDA extended its review of Biogen’s Leqembi Iqlik Alzheimer’s therapy by three months to August 24, 2026, to assess additional submitted data. Investor reaction: Biogen’s stock ...

Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer's market ...